Weishaar R E, Kirker M L, Wallace A M, Ferraris V A, Britton L W, Sim M F
Division of Biological Research, Coromed, Inc., Troy, NY 12180-8343.
Eur J Pharmacol. 1993 Jun 4;236(3):363-6. doi: 10.1016/0014-2999(93)90472-t.
The goal of this study was to assess the relationship between the positive inotropic response to high concentrations of the vasodilators flosequinan and BTS 53 554 (the sulfone metabolite of flosequinan) and the effect of both compounds on different forms of cyclic nucleotide phosphodiesterase. In addition, the relationship between inotropic activity and phosphodiesterase inhibition for the cardiotonic milrinone was also evaluated. All three agents exerted a positive inotropic effect on human cardiac muscle fibers. The concentration of milrinone required to increase cardiac contractility was comparable to the concentration required to inhibit the milrinone-sensitive subclass of cyclic AMP-specific phosphodiesterase (type III phosphodiesterase). However, no such relationship was observed for flosequinan and BTS 53 554. These results suggest that the cardiac response to high concentrations of flosequinan and BTS 53 554 is not mediated by inhibition of type III phosphodiesterase.
本研究的目的是评估高浓度血管扩张剂氟司喹南和BTS 53554(氟司喹南的砜代谢产物)的正性肌力反应与这两种化合物对不同形式环核苷酸磷酸二酯酶的作用之间的关系。此外,还评估了强心剂米力农的正性肌力活性与磷酸二酯酶抑制之间的关系。所有这三种药物对人心脏肌纤维均有正性肌力作用。增加心脏收缩力所需的米力农浓度与抑制环磷酸腺苷特异性磷酸二酯酶(III型磷酸二酯酶)的米力农敏感亚类所需的浓度相当。然而,对于氟司喹南和BTS 53554,未观察到这种关系。这些结果表明,高浓度氟司喹南和BTS 53554引起的心脏反应不是由III型磷酸二酯酶的抑制介导的。